Balstilimab monotherapy data published in gynecologic oncology

Lexington, mass., aug. 26, 2021 (globe newswire) -- agenus inc. (nasdaq: agen), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that results from a global phase 2 clinical study of balstilimab monotherapy in recurrent/metastatic cervical cancer were published online in the international peer reviewed journal gynecologic oncology (https://doi.org/10.1016/j.ygyno.2021.08.018).
AGEN Ratings Summary
AGEN Quant Ranking